Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

May 28, 2026

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
May 27, 2026

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
May 19, 2026

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
May 13, 2026

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
April 30, 2026

Immunic to Participate in Investor and Medical Conferences in May
April 28, 2026

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
April 23, 2026

Immunic, Inc. Announces 1-for-10 Reverse Stock Split
April 9, 2026

Immunic to Participate in Scientific and Medical Conferences in April
April 1, 2026

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 31, 2026

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Show per page